Icagen is an integrated early discovery partner, offering clients specialized technologies and deep scientific expertise to solve myriad challenges and optimize efficiency moving from target to lead. The process begins with druggable targets, and Icagen scientists bring exceptional experience in kinases, GPCR's, ion channels and transporters. Icagen works with clients to determine drug feasibility using state-of-the-art computational chemistry methods. Once a target is selected, Icagen can combine virtual screening, ultra-high throughput screening (uHTS), biology and medicinal chemistry to generate viable leads in a much shorter time than has traditionally been possible.